BCL2 and B-cell chronic lymphocytic leukemia: Recently, treatment with the BCL2-inhibitor venetoclax has demonstrated substantial efficacy, even in high-risk relapsed and chemotherapy-refractory CLL patients with alterations in TP532,15,16.